Biochemical & Biophysical Research Communications. 538 (2021). 163-172.
QUOTE: Cell culture experiments have shown robust antiviral action towards a whole range of viruses, including HIV-1, dengue, Zika and West Nile Virus, Venezuelan equine encephalitis virus, Chikungunya, pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19).
Of the nearly 70 clinical trials currently in progress
worldwide on ivermectin for Covid-19, the available results indicate clinical benefit.
Doses up to 2000 mcg per kg can be tolerated as a single dose, with a very low incidence of serious side effects. It is expected to continue to be on the WHO List of Essential Medicines.
QUOTE: “… where a host-directed agent can be a “game-changer” in treating viral infection may well be in the initial stages of infection or potentially even prophylactically by keeping the viral load low so that the body’s immune system has an opportunity to mount a full antiviral response”
Thank you for following the science and publishing the results.